ArticleThe Journal of clinical and aesthetic dermatology
Topical Corticosteroid Use in Everyday Clinical Practice: Cautionary Tales.
Article in The Journal of clinical and aesthetic dermatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Lindera obtusiloba extract attenuates cytokine-mediated epidermal inflammation in keratinocytes and an MC903-induced AD-like mouse model.Scientific reports · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the development of advanced targeted topical treatments for chronic inflammatory skin diseases and recent calls for caution when prescribing topical corticosteroids (TCS), TCS continue to be the most prescribed dermatologic agent. Yet the perception that adverse effects are uncommon with TCS use persists. To combat this misperception, I selected examples of patients from my practice that illustrate the real-world risks associated with TCS use. This case series provides several key clinical pearls for managing TCS use in everyday clinical practice including: 1) Even using TCS for short periods and as prescribed is not without risks. 2) Long-term TCS use (even intermittent use) can result in permanent skin changes that can even outlast the disease the TCS was used to treat. 3) TCS overuse can have serious adverse effects resulting in hospitalization, including adrenal suppression, infection, and even sepsis. 4) Patients who are dissatisfied with older TCS-sparing treatments might continue to seek more potent TCS, resulting in doctor/clinic hopping and potential TCS misuse. 5) Patients might repurpose TCS prescriptions for other body areas, leading to high-potency TCS being applied to thin-skinned areas and irreversible skin damage.
Indexed as
Identifiers
40735007PMC12303370What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.